Meitav Dash Investments Ltd. Sells 3,695 Shares of SPDR S&P Biotech ETF (NYSEARCA:XBI)

Meitav Dash Investments Ltd. cut its position in SPDR S&P Biotech ETF (NYSEARCA:XBIGet Rating) by 3.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 106,989 shares of the exchange traded fund’s stock after selling 3,695 shares during the quarter. Meitav Dash Investments Ltd. owned approximately 0.14% of SPDR S&P Biotech ETF worth $9,616,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Canada Pension Plan Investment Board lifted its holdings in SPDR S&P Biotech ETF by 200.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 1,200,000 shares of the exchange traded fund’s stock valued at $134,352,000 after purchasing an additional 800,000 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd grew its holdings in SPDR S&P Biotech ETF by 48.4% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 848,000 shares of the exchange traded fund’s stock valued at $94,942,000 after purchasing an additional 276,650 shares during the period. Phoenix Holdings Ltd. grew its holdings in SPDR S&P Biotech ETF by 40.8% during the fourth quarter. Phoenix Holdings Ltd. now owns 799,505 shares of the exchange traded fund’s stock valued at $89,512,000 after purchasing an additional 231,855 shares during the period. Summit Trail Advisors LLC boosted its holdings in shares of SPDR S&P Biotech ETF by 380.0% in the fourth quarter. Summit Trail Advisors LLC now owns 212,843 shares of the exchange traded fund’s stock valued at $23,830,000 after buying an additional 168,499 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich boosted its holdings in shares of SPDR S&P Biotech ETF by 29.3% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 728,810 shares of the exchange traded fund’s stock valued at $81,598,000 after buying an additional 165,265 shares during the period.

SPDR S&P Biotech ETF Price Performance

Shares of XBI stock opened at $92.30 on Friday. The company’s fifty day simple moving average is $76.52 and its 200-day simple moving average is $81.85. SPDR S&P Biotech ETF has a 12 month low of $61.78 and a 12 month high of $136.61.

About SPDR S&P Biotech ETF

(Get Rating)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Articles

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIGet Rating).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.